News | December 26, 2023
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
The plant is yet to start commercial operations
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated
